Styrax

Hyderabad, India Founded: 1995 • Age: 31 yrs Minicorn
Manufacturer supplier of active pharmaceutical ingredients and intermediates

About Styrax

Styrax is a Healthcare company based in Hyderabad (India) founded in 1995. Styrax has raised $2.75 million across 1 funding round from investors including Arora Life Sciences. The company has 260 employees. Styrax was last valued at $8.8 million in July 2017. Its Indian entity Styrax Pharma Private Limited reported revenue of β‚Ή260 Cr. Styrax offers products and services including APIs and Intermediates. Its focus areas include Traditional Pharmaceuticals.

Company details

Manufacturer supplier of active pharmaceutical ingredients and intermediates. It offers a diverse range of active pharmaceutical ingredients and intermediates include Abacavir Sulphate, Emtricitabine USP, Lamivudine, Tenofovir Disoproxil Fumarate, Fluconazole, Itraconazole, Levocetirizine Dihydrochloride, Rifaximin, Duloxetine Hydrochloride and Eltrombopag.

  • Headquarters Hyderabad, India
  • Employees 260
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website styraxpharma.com
  • Social Facebook
  • Legal Name Styrax Pharma Private Limited
  • Date of Incorporation 10 Jul, 1995
  • Jurisdiction Visakhapatnam, Andhra Pradesh, India
Key Metrics
  • Annual Revenue
    ₹260 Cr

    FY 2024 · +4% YoY

  • Net Profit
    ₹9.16 Cr

    FY 2024 · 4% margin

  • EBITDA
    ₹29.31 Cr

    FY 2024 · 11% margin

  • Total Equity Funding
    $2.75M (USD)

    in 1 rounds

  • Latest Funding Round
    $2.75M (USD), Series A

    Jul 2017

  • Employee Count
    260

Products & Services of Styrax

Styrax offers a comprehensive portfolio of products and services, including APIs and Intermediates.

APIs
Pharmaceutical Products

APIs are produced by Styrax Pharma, including various active pharmaceutical ingredients that are manufactured in accordance with quality standards.

Intermediates
Chemical Intermediates

Intermediates are developed by Styrax Pharma for pharmaceutical use, supporting the creation of diverse products in the industry.

Funding Insights of Styrax

Styrax has successfully raised a total of $2.75M through 1 strategic funding round. The most recent funding activity was a Series A round of $2.75 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $2.75M
  • Total Rounds 1
  • Last Round Series A β€” $2.75M
  • First Round $2.75M

    (Jul 2017)

  • Investors Count 1

All 1 funding rounds of Styrax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2017$2.75MSeries A$8.8MArora Life Sciences
–
Valuation history
DateValuationStage
Jul 2017$8.8Mβ€’β€’β€’β€’β€’β€’β€’β€’

Last known valuation $8.8M (Jul 2017). 1 investors in total: 1 institutional.

Investors in Styrax

Styrax has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Arora Life Sciences.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Diversified oral drugs are distributed by Arora Life Sciences.
Jammu, India
Premium access

Investor details for Styrax

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Styrax Pharma Private Limited (Styrax)

Styrax Pharma Private Limited is the primary company behind Styrax. The board of Styrax Pharma Private Limited currently have 3 directors; the longest-serving is Suryadevara Venkateswara Rao, appointed in 2014. 8 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Suryadevara Venkateswara Rao
DIN 00363121
Managing Director23 Jun 201412 yrs 5 moStyrax Pharma Private Limited
Sreenath Suryadevara
DIN 07234232
Director18 Apr 20197 yrs 7 moStyrax Pharma Private Limited
Lakshmi Devi Suryadevara
DIN 06837476
Director18 Apr 20197 yrs 7 moStyrax Pharma Private Limited

People of Styrax

1 people are tracked at Styrax (1 in leadership); the tracked headcount is 260.

NameRoleGroup
Managing DirectorLeadership
Premium access

Complete people profiles for Styrax

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Styrax

Figures of Styrax Pharma Private Limited, the primary company behind Styrax, for FY 2024. Revenue was ₹260 Cr (+4% year on year). Net profit was ₹9.16 Cr (4% margin). EBITDA was ₹29.31 Cr (11% margin). Revenue has grown at a compounded annual rate of -3% over three years.

  • ₹260 CrRevenue · FY 2024 · +4% YoY
  • ₹9.16 CrNet profit · 4% margin
  • ₹29.31 CrEBITDA · 11% margin
  • ₹13.12 CrPaid-up capital
  • 260Employees (provident fund records)
  • -3%Revenue CAGR, 3 years

Balance sheet, profit and loss, cash flow and ratios of Styrax Pharma Private Limited are on its company page.

Premium access

Detailed financial statements for Styrax

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Styrax

3 dated milestones of Styrax across 22 years, from founding to its latest funding, stage changes and deals.

  1. Founded Styrax is founded.
  2. Funding First funding round of $2.7M.
  3. Milestone Reaches Minicorn status.

Web traffic of Styrax

The website of Styrax (styraxpharma.com) receives about 1.1K visits a month.

  • Monthly visits
    1.1K

    ▲ 110.1% vs previous month

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Styrax (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Styrax

Styrax was founded in 1995 and raised its 1st funding round 22 years after it was founded.

Styrax is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Styrax is a funded company, having raised a total of $2.75M across 1 funding round to date. The company's 1st funding round was a Series A of $2.75M, raised on Jul 2017.

Styrax has 260 employees.

The primary company behind Styrax, Styrax Pharma Private Limited, reported revenue of β‚Ή260 Cr for FY 2024, up 4% year on year.

Manufacturer supplier of active pharmaceutical ingredients and intermediates. It offers a diverse range of active pharmaceutical ingredients and intermediates include Abacavir Sulphate, Emtricitabine USP, Lamivudine, Tenofovir Disoproxil Fumarate, Fluconazole, Itraconazole, Levocetirizine Dihydrochloride, Rifaximin, Duloxetine Hydrochloride and Eltrombopag.

Styrax offers APIs and Intermediates.

Styrax has 1 investor. Key investors include Arora Life Sciences.

The valuation of Styrax is $8.8M as of Jul 2017.

Styrax operates through Styrax Pharma Private Limited.

The legal entities of Styrax currently have 4 directors, including Sreenath Suryadevara, Lakshmi Devi Suryadevara, Mohit Mittal and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available